Custom service

Branched Peptides Synthesis

Synthesize branched and dendritic peptide architectures, including map constructs

Turnaround: 3–6 weeksTypical scale: 0.1 mg – 10 g per sequenceChemistry options: multiple-antigen peptide (MAP) dendrimers; Lys-branching monomers (Fmoc-Lys(Fmoc)); branch-point control and QC

The service is built around multiple-antigen peptide (MAP) dendrimers. Depending on the molecule we may move to Lys-branching monomers (Fmoc-Lys(Fmoc)) or branch-point control and QC to improve stability, loading or yield, and every batch is released with branched construct with branch-integrity data.

Because Branched Peptides Synthesis projects usually feed a downstream assay or preclinical study, we lock the release specification early — purity, identity and functional readouts are agreed at quotation, not discovered at delivery.

High-epitope-density immunogens

Multivalent display for binding studies

Branched constructs for clinical dosing

Sequences where a recombinant expression route is objectively cheaper and faster

Release specification is fixed at quotation: standard >95% by HPLC, >98% for assay-critical material. Long chains (>60 residues) are additionally confirmed by MS/MS sequence coverage, and truncated-deletion species are quantified, not just summarized.

Service Highlights

  • Multiple-antigen peptide (MAP) dendrimers as the default route, with Lys-branching monomers (Fmoc-Lys(Fmoc)) held as a proven fallback
  • Branch-point control and QC worked into the design where the application requires it
  • Sequence difficulty analysis (aggregation risk, motif hazards) is done before synthesis, and the route is chosen around it
  • Analytical confirmation of every intermediate before the final release
  • Microwave-assisted coupling and double-coupling are applied automatically where the sequence demands them
  • Branched construct with branch-integrity data delivered with a complete conjugation or synthesis certificate

How the work runs

  1. Sequence analysis

    Branched Peptides Synthesis is analyzed for aggregation risk, motif hazards and puri?cation difficulty before a route is quoted.

  2. Route selection

    Fmoc solid-phase, fragment ligation or hybrid solution-phase is selected and documented.

  3. Assembly

    The chain is built with multiple-antigen peptide (MAP) dendrimers applied where the sequence demands it, with double-coupling at hazard sites.

  4. Cleavage & crude QC

    Crude material is characterized so purification targets are set on data, not hope.

  5. Purification

    RP-HPLC (and ion-exchange where needed) delivers the agreed purity; fractions are pooled on MS confirmation.

  6. Release

    Branched construct with branch-integrity data is documented with the full analytical package and released.

Specifications & timeline

Turnaround
3–6 weeks
Typical scale
0.1 mg – 10 g per sequence
Chemistry options
multiple-antigen peptide (MAP) dendrimers; Lys-branching monomers (Fmoc-Lys(Fmoc)); branch-point control and QC
Deliverable
Branched construct with branch-integrity data
QC package
HPLC purity, ESI/MALDI MS, MS/MS confirmation for long chains
Shipping
Ambient with desiccant; blue ice for modified or sensitive peptides

Related Products

Next step

Tell us the target, we will tell you what is feasible

Send the sequence, assay format and sensitivity you need. You will get a technical assessment — recommended platform, timeline and the risks worth knowing before you commit budget.